Magazine Article | September 24, 2018

Rollout Begins Of Trump's Drug Blueprint

Source: Life Science Leader

By John McManus, The McManus Group

The Trump administration disrupted the typically sleepy August recess with a frenetic release of proposals that implement components of its “blueprint” on drug pricing. The proposals are intended to strengthen the negotiating leverage of Medicare plans over pharmaceutical manufacturers, but physician and patient advocates expressed concern that they may result in impaired patient access to needed drug therapy.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: